| Literature DB >> 34206761 |
Irshad Ul Haq Bhat1, Rajeev Bhat1.
Abstract
Quercetin, a bioactive secondary metabolite, holds incredible importance in terms of bioactivities, which has been proved by in vivo and in vitro studies. The treatment of cardiovascular and neurological diseases by quercetin has been extensively investigated over the past decade. Quercetin is present naturally in appreciable amounts in fresh produce (fruits and vegetables). However, today, corresponding to the growing population and global demand for fresh fruits and vegetables, a paradigm shift and focus is laid towards exploring industrial food wastes and/or byproducts as a new resource to obtain bioactive compounds such as quercetin. Based on the available research reports over the last decade, quercetin has been suggested as a reliable therapeutic candidate for either treating or alleviating health issues, mainly those of cardiovascular and neurological diseases. In the present review, we have summarized some of the critical findings and hypotheses of quercetin from the available databases foreseeing its future use as a potential therapeutic agent to treat cardiovascular and neurological diseases. It is anticipated that this review will be a potential reference material for future research activities to be undertaken on quercetin obtained from fresh produce as well as their respective processing wastes/byproducts that rely on the circular concept.Entities:
Keywords: by-products; cardioprotective and neuroprotective agent; circular economy; fruits and vegetable wastes; quercetin; secondary metabolite
Year: 2021 PMID: 34206761 PMCID: PMC8301140 DOI: 10.3390/biology10070586
Source DB: PubMed Journal: Biology (Basel) ISSN: 2079-7737
Figure 1Quercetin: Sources, structure and uses.
Some recent reports on the role of quercetin as a cardioprotective agent.
| Role | Mode | Reference |
|---|---|---|
| Translocation of NFκB, and expression of TGF-β1, CTGF, and BNP | In vivo | [ |
| Cardioprotective effects restoring plasma thyroid hormone levels and attenuating oxidative stress in the heart | In vivo | [ |
| Inhibition of JNK and p38 mitogen-activated protein kinase signaling pathways | In vivo | [ |
| Inhibits angiotensin-converting enzyme activity, improves vascular relaxation, and decreases oxidative stress and gene expression | In vitro, in vivo | [ |
| Post-ischemic recovery of left ventricular developed pressure, as well as recovery of markers of contraction and relaxation, respectively | In vivo | [ |
| Cardioprotective | In vivo | [ |
| Myocardial infarction | In vivo | [ |
| Myocardial ischemia-reperfusion injury via suppressing the NF-κB pathway | In vivo and in vitro | [ |
| Protein disulfide isomerase (PDI) inhibition for cardiovascular benefits | In vitro | [ |
| Protects cardiomyocytes against oxidative toxicity and the regulation of stress-sensitive protein kinase cascades and transcription factors. | In vitro | [ |
| Lowers ABP in patients with hypertension | In vivo | [ |
| Cardioprotective control | In vitro | [ |
| Endothelial function and reducing inflammation, vascular function, and cardiometabolic health | In vivo | [ |
| Improve cyclosporine-induced cardiotoxicity, as it has antioxidant and anti-inflammatory enzyme activities | In vivo | [ |
| Atherogenic and cardioprotective indices | In vivo | [ |
| Reduction in cardiac and renal markers of oxidative stress | In vivo | [ |
| Antichronic doxorubicin cardiotoxicity via antioxidant and anti-inflammatory properties | In vivo | [ |
| Antioxidative cardiotoxicity and dyslipidemia | In vivo | [ |
| Cardiac weight index and myocardial enzyme activity Antioxidative stress, inhibition of the renin–angiotensin–aldosterone system | In vivo | [ |
| Ischemia/reperfusion injury in cardiomyocytes | In vitro | [ |
| Anti-doxorubicin-induced cardiomyopathy in H9c2 cell; myocardial ischemia/reperfusion injury in rats through the PI3K/Akt pathway | In vitro | [ |
| Induce activation of AMPK and eNOS in human aortic endothelial cells | In vivo | [ |
| Cardioprotective effect of GSK-3b inhibitors | In vivo | [ |
| Reduction of the serum CK-MB, LDH, and SGPT level enzymes | In vivo | [ |
| Protects rat hearts from oxidative stress by its antioxidant potential | In vivo | [ |
| Decrease in doxorubicin-induced cytotoxicity and promoting the cell repair system in cardiomyocyte H9C2 cells | In vitro | [ |
Some recent reports on the role of quercetin as a neuroprotective agent.
| Role | Mode | Reference |
|---|---|---|
| Antioxidant and AChE inhibitory activity | In vitro and in vivo | [ |
| To prevent the increase in AChE activity in the brain, improve the memory and anxiety-like behavior | In vivo | [ |
| Proteasome activities | In vitro | [ |
| Against oxidation-induced neuronal necrotic-such as cell death | In vitro | [ |
| Modulation of neuroinflammation and the cholinergic system | In vivo | [ |
| Neuronal autophagy and brain injury model by activation of PI3K/Akt signaling pathway | In vivo | [ |
| Endoplasmic reticulum stress and neuronal cells | In vitro | [ |
| Reduced oxidative/nitrative damage to DNA, lipids, and proteins of neuroblastoma cell line (SH-SY5Y) cell | In vitro | [ |
| Improves ischemia/reperfusion-induced cognitive deficits. Inhibition of ASK1/JNK3/caspase-3 Akt signaling pathway | In vitro | [ |
| Prevention of brain damage by acrylamide | In vivo | [ |
| Inhibition of μ-calpain protein in hypoxia-induced neuronal injury | In vitro | [ |
| Autophagy-modulating, Parkinson’s diseases | In vivo | [ |
| Deprivation and restoration of oxygen/glucose, increased the expression of Nrf2 | In vitro | [ |
| Neuronal death prevention | In vivo | [ |
| Anti-convulsant | In vivo | [ |
| Inhibition of monoamine oxidase (MAO), AChE, and BChE activities | In vitro | [ |
| Antioxidative insult | In vivo | [ |
| Cerebroprotective action | In vivo | [ |
| Prevention of okadaic-acid-induced injury by MAPK and PI3K/Akt/GSK3β signaling pathways | In vitro | [ |
| Reduction of oxaliplatin-induced oxidative stress in brain | In vitro and in vivo | [ |
| Reduction of immunoreactivity of degenerating neurons | In vivo | [ |
| Parkinson’s disease | In vivo | [ |
| Apoptosis on neural cells via PI3K/Akt signal pathway | In vitro | [ |
| Cerebrovascular disorders | In vivo | [ |
| Alzheimer’s disease (AD) prevention | In vivo | [ |
| Defense of oxidative Stress via PKC- ϵ inactivation/ERK1/2 activation | In vivo | [ |
| Neuropathic pain reliever | In vitro | [ |
| Inhibiting oxidative stress and inflammation in brain injury | In vivo | [ |
| Hypoxic–ischemic brain injury | In vivo | [ |
| Alzheimer’s disease prevention | In vitro | [ |
| Anti-neuroinflammatory | In vitro | [ |
| Enhanced neuronal mitochondrial performance | In vitro | [ |
| Brain therapy, hypoxia | In vivo | [ |
| Anti-inflammatory, antioxidant, and anti-acetylcholinesterase activities in | In vitro | [ |
| Reduction in oxidative-stress-mediated neurodegeneration | In vivo | [ |
| Prevention of Parkinson’s disease by gene expression | In vitro | [ |
| Anti-brain ischemic/reperfusion injury using Akt pathway | In vivo | [ |
| In neuron survival | In vitro | [ |
| Cognitive function | In vivo | [ |
| Antioxidative stress, neuronal damage, | In vivo | [ |
| Protection of human brain cells | In vitro | [ |
| Spatial memory dysfunctions improvement | In vivo | [ |
| Protection of cognitive and emotional functions | In vivo | [ |
| Reduction of cell apoptosis of oxidant-stressed neuroblastoma (SK-N-MC) cells | In vitro | [ |
| Protects the weakening of memory and anxiogenic behavior | In vitro | [ |
| Locomotor activities, neurotransmission | In vivo | [ |
| Spinal cord injury treatment | In vitro | [ |
| Perinatal cerebral hypoxia–ischemia | In vivo | [ |
| Protection from oxidative stress and brain edema | In vivo | [ |
| Brain protection | In vivo and in vitro | [ |
| Retinal neuroprotection | In vivo | [ |
| Brain injury treatment | In vivo | [ |
| Neurolemmocytes damage prevention | In vivo | [ |
| Protection of PC12 neural cells | In vitro | [ |
| Multiple therapeutic molecular targets of Alzheimer diseases | In vitro | [ |
| Reduction of neuroinflammatory response, antidepressant | In vivo | [ |
| Prevention of hippocampal nerve damage, improved memory function | In vivo | [ |
| Neuron density | In vivo | [ |
| Prevention of chemical hypoxia | In vitro | [ |
| Inhibition of glutamate release | In vitro | [ |
| Anxiolytic effects | In vivo | [ |
| Ectoenzymes and acetylcholinesterase activities | In vivo | [ |
| Increases levels of mitochondrial enzyme (PON2) in brain cells | In vivo | [ |
| Nerve protection via Nrf-2/HO-1 activation and NF-κB inhibition | In vivo | [ |
| Catalepsy normalization, improvement of neurochemical parameters | In vivo | [ |
| Suppression of cellular acetylcholinesterase (AChE), protection against oxidative stress | In vitro | [ |
| Preventive medicine for polychlorinated biphenyls (PCBs)-induced neurotoxicity | In vivo | [ |
| Cerebral ischemia–reperfusion injury treatment | In vivo | [ |
| Protection against induced neurobehavioral impairments | In vivo | [ |
| Neuroprotection in mitochondrial neurotoxin-induced Parkinson diseases | In vivo | [ |
| Neurovascular coupling protection, decrease in neurovascular oxidation | In vivo | [ |
| Neuronal protection | In vivo | [ |
| Neuroprotection against brain oxidative stress | In vivo | [ |
| Against neuron death | In vivo | [ |
| Against neurotoxic venoms | In vitro | [ |
| Neurodegeneration protection via production of ROS scavenging | In vivo | [ |
| Neuroprotection in ypoxic–ischemic brain injury | In vivo | [ |
| Neuroprotection in duodenum enteric nervous system | In vivo | [ |
| Alcoholic neuropathy protection | In vivo | [ |
| Protection in cerebral ischemia through activation of BDNF-TrkB-PI3K/Akt signaling pathway | In vivo | [ |
| Prevention of oxidative stress in brain | In vivo | [ |
| Reversal of hypobaric hypoxia, neuroprotective response stimulant | In vivo | [ |
| Diabetic neuropathy prevention | In vivo | [ |
| Prevention of oxidative damage by induced neurotoxicity | In vitro | [ |
| Prevention of cerebral ischemia-induced oxidative stress | In vivo | [ |
| Neuroinflammation prevention | In vitro | [ |
| Cerebral ischemia protection | In vitro | [ |
| Protection Oxidative injury P19 neurons | In vitro | [ |
| Lutamate-induced neurotoxicity protection in HT22 cells | In vitro | [ |
| Neuron cell protection | In vitro | [ |
| Oxidative stress | In vivo | [ |
| Decreases the neuronal damage and scavenged free radicals | In vivo | [ |
| Protection for cerebral ischemic conditions | In vivo | [ |
| Neurodegeneration protection | In vivo | [ |
Quercetin in food industrial wastes and byproducts.
| Waste/By-Products | Quantity (mg/g) * | Reference |
|---|---|---|
| Tomato peels | 9.97 ± 0.27 | [ |
| Berry peel | 0.0001 ± 0.00 | [ |
| Lotus byproducts | (Only detected not quantified) | [ |
| Coppery onion outer dry layers | 52.84 ± 0.12 | [ |
| Red grape pomace | 0.05 ± 0.00 | [ |
| Cacao beans pod husk | 0.6018 ± 0.0112 | [ |
| Grape pomace | 0.03189 ± 0.00277 | [ |
| Grape pomace | 0.24923 ± 0.00114 | [ |
| Onion waste | (A case study of industrial scale, output yield is in Kgs) | [ |
| Black currant residue with quercetin glycoside (based on the place of cultivation) | 34.6 ± 5.7 | [ |
* The units presented are converted to (mg/g) as compared to different units reported in the references.